Our Mission

We are an emerging leader at the forefront of innovating transformational therapies that address the root cause of age-related degenerative disease

Our Vision

We aim to shift the treatment paradigm for age-related degenerative disease to improve the lives of millions of patients and their families around the world

Our Story

Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age-related degenerative disease. Today, the majority of treatments for these diseases are palliative, with a focus on alleviating symptoms alone. As pioneers in the science surrounding programmed cell death mechanisms and their connection to age-related degenerative disease, Sironax was founded in 2017 by Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, who recognized the growing need for therapies that could directly address disease pathology.

Since our founding, we have been hard at work developing our pathway-driven portfolio strategy which has enabled us to establish a pipeline of novel therapies that address a wide range of age-related degenerative diseases and underlying mechanisms, including regulated cell death, neuroprotective pathways, neuroinflammation, among others. To date, our pipeline contains seven innovative programs spanning small and large molecules, all of which are global first-in-class or front-runners. Our lead RIPK1 program is comprised of several chemically differentiated small molecule inhibitors, including SIR0365—which has completed two Phase 1b patient studies—in addition to SIR2446, which is now in a Phase 1a study in healthy volunteers. In parallel, we continue to expand our R&D footprint, with plans to advance additional programs into clinic over the next several years.

With operations in China and the U.S., Sironax presently has 180 employees and growing and we continue to build our global team of highly skilled chemists, biologists, manufacturing experts, biomarker scientists and clinicians. Along with decades of experience in global pharmaceutical R&D, our team shares a collective vision of shifting the treatment paradigm for age-related degenerative disease to ultimately improve the lives of millions of patients and their families around the world.

  • 2022-08
    Series B financing
  • 2021-12
    • First healthy subject dosed for SIR2446
    • SIR0365 first Ph1b patient study topline data readout
  • 2021-09
    Biologics programs jump-started
  • 2021-08
    Second Ph1b study initiated for SIR0365
  • 2020-12
    First Ph1b patient study initiated SIR0365
  • 2020-08
    Healthy subject Ph1a completed for SIR0365
  • 2019-11
    First healthy subject dosed for SIR0365
  • 2019-09
    Series A financing
  • 2019-04
    First RIPK1i preclinical candidate SIR0365 nominated
  • 2018-06
    Seed financing
  • 2017-09
    Sironax (Cayman) founded